TARGETING BCL2 TO INCREASE ENZALUTAMIDE SENSITIVITY TO BETTER SUPPRESS PROSTATE CANCER PROGRESSION THROUGH ALTERING ARV7 PROTEIN DEGRADATION

被引：0
|
作者：
Xu, Hua
机构：
来源：
JOURNAL OF UROLOGY | 2020年 / 203卷
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD59-11
引用
收藏
页码：E1209 / E1209
页数：1
相关论文
共 28 条
  • [1] Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
    Xu, Hua
    Sun, Yin
    Huang, Chi-Ping
    You, Bosen
    Ye, Dingwei
    Chang, Chawnshang
    CANCERS, 2020, 12 (04)
  • [2] The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer
    Liu, Bianjiang
    Sun, Yin
    Tang, Min
    Liang, Chao
    Huang, Chi-Ping
    Niu, Yuanjie
    Wang, Zengjun
    Chang, Chawnshang
    CELL DEATH & DISEASE, 2020, 11 (09)
  • [3] The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer
    Bianjiang Liu
    Yin Sun
    Min Tang
    Chao Liang
    Chi-Ping Huang
    Yuanjie Niu
    Zengjun Wang
    Chawnshang Chang
    Cell Death & Disease, 11
  • [4] A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
    Yan Li
    Ya Chu
    Guangjiang Shi
    Xiaobin Wang
    Wanli Ye
    Chun Shan
    Dajia Wang
    Di Zhang
    Wei He
    Jingwei Jiang
    Shuqian Ma
    Yuhong Han
    Zhili Zhao
    Shijia Du
    Zhen Chen
    Zhiyu Li
    Yong Yang
    Chen Wang
    Xi Xu
    Hongxi Wu
    ActaPharmaceuticaSinicaB, 2022, 12 (11) : 4165 - 4179
  • [5] A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
    Li, Yan
    Chu, Ya
    Shi, Guangjiang
    Wang, Xiaobin
    Ye, Wanli
    Shan, Chun
    Wang, Dajia
    Zhang, Di
    He, Wei
    Jiang, Jingwei
    Ma, Shuqian
    Han, Yuhong
    Zhao, Zhili
    Du, Shijia
    Chen, Zhen
    Li, Zhiyu
    Yang, Yong
    Wang, Chen
    Xu, Xi
    Wu, Hongxi
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (11) : 4165 - 4179
  • [6] Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
    Fu-Ju Chou
    ChangYi Lin
    Hao Tian
    WanYing Lin
    Bosen You
    Jieyang Lu
    Deepak Sahasrabudhe
    Chi-Ping Huang
    Vanessa Yang
    Shuyuan Yeh
    Yuanjie Niu
    Chawnshang Chang
    Cell Death & Disease, 11
  • [7] PRECLINICAL STUDIES USING CISPLATIN/CARBOPLATIN TO RESTORE THE ENZALUTAMIDE SENSITIVITY VIA DEGRADING THE ANDROGEN RECEPTOR SPLICING VARIANT 7 (ARV7) TO FURTHER SUPPRESS ENZALUTAMIDE RESISTANT PROSTATE CANCER
    Chou, Fu-Ju
    Hu, Yixi
    Lin, ChangYi
    Tian, Hao
    Sahasrabudhe, Deepak
    Joseph, Jean
    Messing, Edward M.
    Yeh, Shuyuan
    Chang, Chawnshang
    JOURNAL OF UROLOGY, 2022, 207 (05) : E792 - E793
  • [8] Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
    Chou, Fu-Ju
    Lin, ChangYi
    Tian, Hao
    Lin, WanYing
    You, Bosen
    Lu, Jieyang
    Sahasrabudhe, Deepak
    Huang, Chi-Ping
    Yang, Vanessa
    Yeh, Shuyuan
    Niu, Yuanjie
    Chang, Chawnshang
    CELL DEATH & DISEASE, 2020, 11 (11)
  • [9] Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7)
    Lin, Shin-Jen
    Chou, Fu-Ju
    Li, Lei
    Lin, Chang-Yi
    Yeh, Shuyuan
    Chang, Chawnshang
    CANCER LETTERS, 2017, 398 : 62 - 69
  • [10] Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression
    Cao, Hongwen
    Wang, Dan
    Gao, Renjie
    Chen, Lei
    Feng, Yigeng
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 541 : 56 - 62
123